dupilumab
sanofi,regeneron
['derm', 'regeneron', 'sanofi']
at #aad2023, we re presenting late-breaking phase 3 data from a clinical trial in patients with #atopicdermatitis of the hands and feet. read more: 
Official SanofiUS Twitter feed. We chase the miracles of science to improve people’s lives. For U.S. residents only. https://t.co/pxa3Cnagpq